Literature DB >> 25738867

Immunohistochemical profile of cytokines and growth factors expressed in vestibular schwannoma and in normal vestibular nerve tissue.

Samanta Taurone1, Enrica Bianchi1, Giuseppe Attanasio1, Cira Di Gioia2, Rocco Ierinó2, Cecilia Carubbi3, Daniela Galli3, Francesco Saverio Pastore4, Felice Giangaspero2, Roberto Filipo1, Christian Zanza1, Marco Artico1.   

Abstract

Vestibular schwannomas, also known as acoustic neuromas, are benign tumors, which originate from myelin-forming Schwann cells. They develop in the vestibular branch of the eighth cranial nerve in the internal auditory canal or cerebellopontine angle. The clinical progression of the condition involves slow and progressive growth, eventually resulting in brainstem compression. The objective of the present study was to investigate the expression level and the localization of the pro-inflammatory cytokines, transforming growth factor-β1 (TGF-β1) interleukin (IL)-1β, IL-6 and tumor necrosis factor-α (TNF-α), as well as the adhesion molecules, intracellular adhesion molecule-1 and vascular endothelial growth factor (VEGF), in order to determine whether these factors are involved in the transformation and development of human vestibular schwannoma. The present study investigated whether changes in inflammation are involved in tumor growth and if so, the mechanisms underlying this process. The results of the current study demonstrated that pro-inflammatory cytokines, including TGF-β1, IL-1β and IL-6 exhibited increased expression in human vestibular schwannoma tissue compared with normal vestibular nerve samples. TNF-α was weakly expressed in Schwann cells, confirming that a lower level of this cytokine is involved in the proliferation of Schwann cells. Neoplastic Schwann cells produce pro-inflammatory cytokines that may act in an autocrine manner, stimulating cellular proliferation. In addition, the increased expression of VEGF in vestibular schwannoma compared with that in normal vestibular nerve tissue, suggests that this factor may induce neoplastic growth via the promotion of angiogenesis. The present findings suggest that inflammation may promote angiogenesis and consequently contribute to tumor progression. In conclusion, the results of the present study indicated that VEGF and pro-inflammatory cytokines may be potential therapeutic targets in vestibular schwannoma. Further studies are necessary to confirm the involvement of these factors in the growth of neoplasms and to develop inhibitors of pro-inflammatory cytokines as a potential treatment option in the future.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25738867     DOI: 10.3892/mmr.2015.3415

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  10 in total

Review 1.  Beyond Antoni: A Surgeon's Guide to the Vestibular Schwannoma Microenvironment.

Authors:  Cathal J Hannan; Daniel Lewis; Claire O'Leary; Carmine A Donofrio; Dafydd G Evans; Emma Stapleton; Simon R Freeman; Simon K Lloyd; Scott A Rutherford; Charlotte Hammerbeck-Ward; David Brough; Stuart M Allan; David Coope; Andrew T King; Omar N Pathmanaban
Journal:  J Neurol Surg B Skull Base       Date:  2020-09-10

2.  Identification of key pathways and genes in vestibular schwannoma using bioinformatics analysis.

Authors:  Bo Wu; Gaojing Dou; Yuan Zhang; Jing Wang; Xinhui Wang; Shanshan Jiang; Sheng Zhong; Junan Ren; Zhiyun Zhang; Jiahui Li; Chunjia Sheng; Gang Zhao; Liyan Zhao
Journal:  Exp Ther Med       Date:  2022-01-13       Impact factor: 2.447

3.  Case Report: Extensive Temporal Bone Invasion in a Giant Vestibular Schwannoma.

Authors:  Fang Lyu; Jinlu Gan; Haijun Wang; Hongyang Zhao; Lei Wang; Fangcheng Zhang
Journal:  Front Surg       Date:  2022-05-25

4.  The Role of Tumor Necrosis Factor Alpha (TNFα)in Hearing Loss and Vestibular Schwannomas.

Authors:  Yin Ren; Konstantina M Stankovic
Journal:  Curr Otorhinolaryngol Rep       Date:  2018-02-17

5.  COX2 expression is associated with proliferation and tumor extension in vestibular schwannoma but is not influenced by acetylsalicylic acid intake.

Authors:  Felix Behling; Vanessa Ries; Marco Skardelly; Irina Gepfner-Tuma; Martin Schuhmann; Florian-Heinrich Ebner; Ghazaleh Tabatabai; Antje Bornemann; Jens Schittenhelm; Marcos Tatagiba
Journal:  Acta Neuropathol Commun       Date:  2019-07-11       Impact factor: 7.801

6.  Serum Levels of APRIL Increase in Patients with Glioma, Meningioma and Schwannoma

Authors:  Hamed Fouladseresht; Seyyed Mohyeddin Ziaee; Nasrollah Erfani; Mehrnoosh Doroudchi
Journal:  Asian Pac J Cancer Prev       Date:  2019-03-26

7.  The Lipid Asset Is Unbalanced in Peripheral Nerve Sheath Tumors.

Authors:  Ignazio G Vetrano; Michele Dei Cas; Vittoria Nazzi; Marica Eoli; Niccolò Innocenti; Veronica Saletti; Antonella Potenza; Tatiana Carrozzini; Giuliana Pollaci; Gemma Gorla; Rita Paroni; Riccardo Ghidoni; Laura Gatti
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

8.  Tumor-Associated Macrophages in Vestibular Schwannoma and Relationship to Hearing.

Authors:  Eric Nisenbaum; Carly Misztal; Mikhaylo Szczupak; Torin Thielhelm; Stefanie Peña; Christine Mei; Stefania Goncalves; Olena Bracho; Ruixuan Ma; Michael E Ivan; Jacques Morcos; Fred Telischi; Xue-Zhong Liu; Cristina Fernandez-Valle; Christine T Dinh
Journal:  OTO Open       Date:  2021-11-23

9.  Elevated baseline C-reactive protein levels predict poor progression-free survival in sporadic vestibular schwannoma.

Authors:  Johannes Wach; Ági Güresir; Valeri Borger; Patrick Schuss; Albert Becker; Christoph Coch; Marie-Therese Schmitz; Michael Hölzel; Marieta Toma; Ulrich Herrlinger; Hartmut Vatter; Erdem Güresir
Journal:  J Neurooncol       Date:  2021-12-09       Impact factor: 4.130

10.  Inflammation and vascular permeability correlate with growth in sporadic vestibular schwannoma.

Authors:  Daniel Lewis; Federico Roncaroli; Erjon Agushi; Dominic Mosses; Ricky Williams; Ka-Loh Li; Xiaoping Zhu; Rainer Hinz; Ross Atkinson; Andrea Wadeson; Sharon Hulme; Helen Mayers; Emma Stapleton; Simon K L Lloyd; Simon R Freeman; Scott A Rutherford; Charlotte Hammerbeck-Ward; D Gareth Evans; Omar Pathmanaban; Alan Jackson; Andrew T King; David J Coope
Journal:  Neuro Oncol       Date:  2019-02-19       Impact factor: 12.300

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.